9
Participants
Start Date
August 31, 2007
Primary Completion Date
February 28, 2011
Study Completion Date
January 31, 2013
therapeutic autologous lymphocytes
Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
Use of an artificial antigen presenting cell (aAPC) to generate CTL
A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
GM-CSF
GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
Irradiation of cutaneous tumor lesion
Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute
OTHER